Intranasal Dexmedetomidine and Zolpidem for Treatment of Primary Insomnia
Insomnia
About this trial
This is an interventional treatment trial for Insomnia focused on measuring Insomnia, Dexmedetomidine, Zolpidem
Eligibility Criteria
Inclusion Criteria: Participants aged between 18 to 25 years, with DSM-5 insomnia disorder. Insomnia will be diagnosed and confirmed by a clinical interview and will have an Insomnia Severity Index score of ≥ 15. Exclusion Criteria: Comorbid diagnosis of psychiatric disorders ( major depression, anxiety disorders, bipolar disorders and psychotic disorders) Obstructive sleep apnoea as determined by an Apnea Hypoapnea Index of >15 or snoring. Restless legs, or periodic limb movements during sleep as measured by the Periodic Limb Movements Index with arousal of > 15 per hour Obesity (body mass index > 30) Known or suspected cardiovascular, pulmonary, metabolic disease or diabetes as confirmed by the clinician interview during recruitment Pregnancy Anyone who has taken trans-meridian travel across more than one time-zone or worked night shifts in the preceding three months Consuming prescribed or non-prescription sleep medication in the past month
Sites / Locations
- HKU Li Ka Shing Faculty of MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Placebo Comparator
Dexmedetomidine
Zolpidem
Placebo